About Us
Fund
Support
Return
Our Companies
left
About Us
Our Companies
Our DNA
Fund
Our Investment Strategy
Our Investors
Our Funds
Our Charity Fund
Support
Our Value Creation
Our Team and Network
Return
Return to Investors
Return to People
Return to Society
right
News
JOIN OUR TEAM
Investor Portal
Contact
NEWS
Our Latest News
Majority owner ARCHIMED and its partners fund three add-on acquisitions by diversified European health safety testing company, CARSO
View All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Majority owner ARCHIMED and its partners fund three add-on acquisitions by diversified European health safety testing company, CARSO
May
15,
2024
ARCHIMED buys Cellese, a pioneering developer of growth factors and exosome-based skincare products
May
15,
2024
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
May
15,
2024
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
May
15,
2024
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
May
15,
2024
ARCHIMED Publishes White Paper – “Navigating the FHIR Landscape: A Strategic Approach for Healthcare IT Businesses”
September
27,
2023
1
2
3
…
14
>
368